Body Fluid Analysis Market by Product (Consumables, Instruments), Technology (Immunoassay, PCR, Flow Cytometry), Fluid Type (CSF, Pleural, Synovial, Peritoneal, Semen), Application (Clinical Diagnostics, Forensic, Research) - Global Forecast to 2031

1 INTRODUCTION 30 1.1 STUDY OBJECTIVES 30 1.2 MARKET DEFINITION 30 1.3 STUDY SCOPE 31 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 31 1.3.2 INCLUSIONS AND EXCLUSIONS 32 1.3.3 YEARS CONSIDERED 32 1.3.4 CURRENCY CONSIDERED 32 1.4 STAKEHOLDERS 33 1.5 SUMMARY OF CHANGES 33 2 EXECUTIVE SUMMARY 35 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 35 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 36 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 37 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 38 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 39 3 PREMIUM INSIGHTS 40 3.1 BODY FLUID ANALYSIS MARKET OVERVIEW 40 3.2 BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2026 VS. 2031 40 3.3 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2026 VS. 2031 41 3.4 BODY FLUID ANALYSIS MARKET, BY TYPE, 2026 VS. 2031 41 3.5 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2026 VS. 2031 42 3.6 BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2026 VS. 2031 42 3.7 BODY FLUID ANALYSIS MARKET, BY END USER, 2026 VS. 2031 43 3.8 BODY FLUID ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 43 4 MARKET OVERVIEW 44 4.1 INTRODUCTION 44 4.2 MARKET DYNAMICS 44 4.2.1 DRIVERS 45 4.2.1.1 Growing global infectious disease, inflammatory disease, and cancer burden necessitating body fluid analysis 45 4.2.1.2 Increasing prevalence of reproductive health conditions and infertility 45 4.2.1.3 Growing awareness of early disease detection 46 4.2.2 RESTRAINTS 47 4.2.2.1 Limited and inconsistent reimbursement for advanced body fluid testing 47 4.2.2.2 High cost of instruments and consumables 47 4.2.2.3 Shortage of skilled laboratory personnel 48 4.2.3 OPPORTUNITIES 49 4.2.3.1 Expansion potential across emerging economies 49 4.2.3.2 Advancements in diagnostic technologies 49 4.2.4 CHALLENGES 50 4.2.4.1 Stringent and varying regulatory requirements 50 4.2.4.2 Supply chain disruptions for reagents and kits 51 4.3 UNMET NEEDS AND WHITE SPACES 52 4.3.1 UNMET NEEDS IN BODY FLUID ANALYSIS MARKET 52 4.3.2 WHITE SPACE OPPORTUNITIES 53 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 54 4.4.1 INTERCONNECTED MARKETS 54 4.4.2 CROSS-SECTOR OPPORTUNITIES 55 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 56 4.5.1 KEY MOVES AND STRATEGIC FOCUS 56 5 INDUSTRY TRENDS 57 5.1 PORTER’S FIVE FORCES ANALYSIS 57 5.1.1 BARGAINING POWER OF SUPPLIERS 58 5.1.2 BARGAINING POWER OF BUYERS 58 5.1.3 THREAT OF NEW ENTRANTS 58 5.1.4 THREAT OF SUBSTITUTES 59 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 59 5.2 MACROECONOMIC OUTLOOK 59 5.2.1 INTRODUCTION 59 5.2.2 GDP TRENDS AND FORECAST 59 5.3 SUPPLY CHAIN ANALYSIS 62 5.4 VALUE CHAIN ANALYSIS 63 5.5 ECOSYSTEM ANALYSIS 65 5.5.1 BODY FLUID ANALYSIS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 65 5.6 PRICING ANALYSIS 66 5.6.1 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY KEY PLAYER, 2024–2026 66 5.6.2 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY REGION, 2024–2026 67 5.7 TRADE ANALYSIS 68 5.7.1 IMPORT SCENARIO (HS CODE 3822) 68 5.7.2 EXPORT SCENARIO (HS CODE 3822) 69 5.8 KEY CONFERENCES & EVENTS, 2026–2027 70 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71 5.10 INVESTMENT & FUNDING SCENARIO 71 5.11 CASE STUDY ANALYSIS 72 5.11.1 CASE STUDY 1: IMPLEMENTATION OF AUTOMATED CSF ALZHEIMER’S BIOMARKER TESTING USING ROCHE ELECSYS ASSAYS 72 5.11.2 CASE STUDY 2: IMPLEMENTATION OF AUTOMATED BODY FLUID CELL COUNTING USING BECKMAN COLTER UNICEL DXH SERIES 73 5.11.3 CASE STUDY 3: POINT-OF-CARE TESTING FOR PLEURAL, PERITONEAL, AND CSF ANALYSIS 73 5.12 IMPACT OF US TARIFFS—BODY FLUID ANALYSIS MARKET 74 5.12.1 INTRODUCTION 74 5.12.2 KEY TARIFF RATES 74 5.12.3 PRICE IMPACT ANALYSIS 75 5.12.4 IMPACT ON COUNTRIES/REGIONS 75 5.12.4.1 North America 75 5.12.4.2 Europe 75 5.12.4.3 Asia Pacific 76 5.12.5 IMPACT ON END-USE INDUSTRIES 76 5.12.5.1 Diagnostic laboratories 76 5.12.5.2 Hospital laboratories 76 5.12.5.3 Forensic laboratories 77 5.12.5.4 Academic & research institutes 77 5.12.5.5 Pharmaceutical & biotechnology companies 77 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 78 6.1 KEY EMERGING TECHNOLOGIES 78 6.1.1 FLOW CYTOMETRY 78 6.1.2 PCR 78 6.2 COMPLEMENTARY TECHNOLOGIES 79 6.2.1 BIOINFORMATICS & DATA ANALYTICS PLATFORMS 79 6.3 ADJACENT TECHNOLOGIES 80 6.3.1 DIGITAL PCR (DPCR) 80 6.4 TECHNOLOGY/PRODUCT ROADMAP 80 6.5 PATENT ANALYSIS 82 6.5.1 LIST OF MAJOR PATENTS 83 6.6 FUTURE APPLICATIONS 84 6.7 IMPACT OF AI/GENERATIVE AI ON BODY FLUID ANALYSIS MARKET 85 6.7.1 INTRODUCTION 85 6.7.2 TOP USE CASES AND MARKET POTENTIAL 86 6.7.3 KEY COMPANIES IMPLEMENTING AI 87 6.7.4 FUTURE OF AI 87   7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 88 7.1 REGIONAL REGULATIONS AND COMPLIANCE 88 7.1.1 REGULATORY ANALYSIS 88 7.1.1.1 North America 88 7.1.1.1.1 US 88 7.1.1.1.2 Canada 88 7.1.1.2 Europe 88 7.1.1.2.1 Germany 89 7.1.1.2.2 UK 89 7.1.1.2.3 France 90 7.1.1.2.4 Italy 90 7.1.1.3 Asia Pacific 90 7.1.1.3.1 China 90 7.1.1.3.2 Japan 90 7.1.1.3.3 India 91 7.1.1.4 Latin America 91 7.1.1.4.1 Brazil 91 7.1.1.4.2 Mexico 92 7.1.1.5 Middle East 92 7.1.1.5.1 Africa 92 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 7.2 SUSTAINABILITY INITIATIVES 94 7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN BODY FLUID ANALYSIS MARKET 94 7.2.1.1 Eco-friendly Initiatives 95 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 96 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 97 8.1 DECISION-MAKING PROCESS 97 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 97 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 97 8.2.2 BUYING CRITERIA 98 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 99 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 100 8.5 MARKET PROFITABILITY 102 8.5.1 REVENUE POTENTIAL 102 8.5.2 COST DYNAMICS 102 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 103   9 BODY FLUID ANALYSIS MARKET, BY PRODUCT 104 9.1 INTRODUCTION 105 9.2 CONSUMABLES 105 9.2.1 ONGOING INNOVATIONS IN BODY FLUID ANALYSIS TO SPUR GROWTH 105 9.3 INSTRUMENTS 109 9.3.1 TECHNOLOGICAL ADVANCEMENTS TO FOSTER MARKET GROWTH 109 10 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY 112 10.1 INTRODUCTION 113 10.2 MICROSCOPIC EXAMINATION 113 10.2.1 GROWING ADOPTION OF AUTOMATED AND DIGITAL MICROSCOPY TO DRIVE MARKET 113 10.3 CLINICAL CHEMISTRY 117 10.3.1 RISING DEMAND FOR RAPID AND ACCURATE BIOCHEMICAL ASSESSMENT FUELS ADOPTION OF CLINICAL CHEMISTRY TECHNOLOGY 117 10.4 FLOW CYTOMETRY 120 10.4.1 ADVANCEMENTS IN MULTIPARAMETRIC ANALYSIS AND AUTOMATION DRIVE THE MARKET GROWTH 120 10.5 IMMUNOASSAY 122 10.5.1 INCREASING USE OF IMMUNOASSAYS IN CANCER AND INFECTIOUS DISEASE TESTING TO AID GROWTH 122 10.6 POLYMERASE CHAIN REACTION 125 10.6.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH 125 10.7 OTHER TECHNOLOGIES 128 11 BODY FLUID ANALYSIS MARKET, BY TYPE 131 11.1 INTRODUCTION 132 11.2 COLLECTION DEVICES 132 11.2.1 RISING DEMAND FOR ACCURATE SPECIMEN COLLECTION AND HANDLING TO PROMOTE GROWTH 132 11.3 DIAGNOSTIC PRODUCTS 135 11.3.1 TECHNOLOGICAL ADVANCEMENTS TO AUGMENT GROWTH 135 12 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE 139 12.1 INTRODUCTION 140 12.2 CEREBROSPINAL FLUID 140 12.2.1 INCREASING BURDEN OF NEUROLOGICAL DISORDERS SUPPORTS MARKET GROWTH 140 12.3 PLEURAL FLUID 142 12.3.1 TECHNOLOGICAL ADVANCEMENTS IMPROVING DIAGNOSTIC ACCURACY OF PLEURAL FLUID TESTING TO DRIVE MARKET 142   12.4 PERITONEAL FLUID 145 12.4.1 RISING PREVALENCE OF LIVER DISORDERS AND MALIGNANT ASCITES DRIVES MARKET 145 12.5 SYNOVIAL FLUID 148 12.5.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET 148 12.6 SEMEN 150 12.6.1 DECLINING MALE REPRODUCTIVE HEALTH DRIVING DEMAND FOR SEMEN ANALYSIS 150 12.7 PERICARDIAL FLUID 153 12.7.1 GROWING UTILIZATION OF PERICARDIAL FLUID TESTING IN CLINICAL PRACTICES TO DRIVE MARKET 153 13 BODY FLUID ANALYSIS MARKET VOLUME ANALYSIS, BY FLUID TYPE (NUMBER OF TESTS) 156 14 BODY FLUID ANALYSIS MARKET, BY APPLICATION 157 14.1 INTRODUCTION 158 14.2 CLINICAL DIAGNOSTICS 158 14.2.1 INFECTIOUS DISEASES 161 14.2.1.1 Rising burden of infectious diseases drives adoption of body fluid analysis 161 14.2.2 INFLAMMATORY DISEASES 164 14.2.2.1 Growing burden of autoimmune and inflammatory diseases supports market growth 164 14.2.3 CANCER 167 14.2.3.1 Rising burden of cancer to fuel growth 167 14.2.4 OTHER DISEASES 169 14.3 FORENSICS 172 14.3.1 GROWING UTILIZATION OF BODY FLUID ANALYSIS IN FORENSIC AND MEDICO-LEGAL INVESTIGATIONS TO SUPPORT MARKET 172 14.4 RESEARCH 175 14.4.1 INCREASING USE OF BODY FLUID ANALYSIS IN BIOMEDICAL RESEARCH AND BIOMARKER DISCOVERY TO BOOST MARKET 175 15 BODY FLUID ANALYSIS MARKET, BY END USER 178 15.1 INTRODUCTION 179 15.2 HOSPITAL LABORATORIES 179 15.2.1 RISING HEALTHCARE INVESTMENT TO CONTRIBUTE TO GROWTH 179 15.3 DIAGNOSTIC LABORATORIES 182 15.3.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET 182 15.4 FORENSIC LABORATORIES 185 15.4.1 ADVANCEMENTS IN FORENSIC TESTING AND LABORATORY INFORMATICS SUPPORT MARKET GROWTH 185 15.5 ACADEMIC & RESEARCH INSTITUTES 187 15.5.1 ADVANCEMENTS IN RESEARCH TO BOOST MARKET 187 15.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 190 15.6.1 INCREASING ADOPTION OF BIOMARKER-DRIVEN DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH 190 16 BODY FLUID ANALYSIS MARKET, BY REGION 193 16.1 INTRODUCTION 194 16.2 NORTH AMERICA 195 16.2.1 US 200 16.2.1.1 Presence of advanced healthcare infrastructure to augment growth 200 16.2.2 CANADA 204 16.2.2.1 Favorable government initiatives to fuel market 204 16.3 EUROPE 208 16.3.1 GERMANY 211 16.3.1.1 Increasing healthcare expenditure to advance growth 211 16.3.2 UK 216 16.3.2.1 Growing number of diagnostic centers to fuel market 216 16.3.3 FRANCE 219 16.3.3.1 Increasing demand for early disease diagnosis to augment growth 219 16.3.4 ITALY 223 16.3.4.1 Growing adoption of advanced diagnostic technologies to fuel market 223 16.3.5 SPAIN 226 16.3.5.1 Increased government initiatives to boost market 226 16.3.6 REST OF EUROPE 229 16.4 ASIA PACIFIC 233 16.4.1 CHINA 237 16.4.1.1 Rising public access to modern healthcare to spur growth 237 16.4.2 JAPAN 240 16.4.2.1 Universal healthcare reimbursement policy to foster growth 240 16.4.3 INDIA 243 16.4.3.1 Increased government investments for healthcare sector to bolster growth 243 16.4.4 REST OF ASIA PACIFIC 247 16.5 LATIN AMERICA 252 16.5.1 RISING DISEASE INCIDENCE AND HEALTHCARE INFRASTRUCTURAL IMPROVEMENTS TO DRIVE MARKET 252 16.6 MIDDLE EAST & AFRICA 256 16.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH 256   17 COMPETITIVE LANDSCAPE 260 17.1 INTRODUCTION 260 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 260 17.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BODY FLUID ANALYSIS MARKET 260 17.3 REVENUE ANALYSIS, 2023–2025 262 17.4 MARKET SHARE ANALYSIS, 2025 263 17.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 263 17.4.2 US MARKET SHARE ANALYSIS, 2025 265 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 265 17.5.1 STARS 265 17.5.2 EMERGING LEADERS 265 17.5.3 PERVASIVE PLAYERS 266 17.5.4 PARTICIPANTS 266 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 267 17.5.5.1 Company footprint 267 17.5.5.2 Region footprint 267 17.5.5.3 Product footprint 268 17.5.5.4 Type footprint 269 17.5.5.5 Application footprint 269 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 270 17.6.1 PROGRESSIVE COMPANIES 270 17.6.2 RESPONSIVE COMPANIES 270 17.6.3 DYNAMIC COMPANIES 270 17.6.4 STARTING BLOCKS 270 17.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 272 17.6.5.1 Detailed list of key startups/SMEs 272 17.6.5.2 Competitive benchmarking of startups/SMEs 272 17.7 COMPANY VALUATION & FINANCIAL METRICS 273 17.7.1 FINANCIAL METRICS 273 17.7.2 COMPANY VALUATION 274 17.8 PRODUCT COMPARISON 274 17.9 COMPETITIVE SCENARIO 275 17.9.1 PRODUCT LAUNCHES & APPROVALS 275 17.9.2 DEALS 276 17.9.3 EXPANSIONS 277   18 COMPANY PROFILES 278 18.1 KEY PLAYERS 278 18.1.1 DANAHER 278 18.1.1.1 Business overview 278 18.1.1.2 Products offered 279 18.1.1.3 Recent developments 281 18.1.1.3.1 Deals 281 18.1.1.4 MnM view 281 18.1.1.4.1 Key strengths 281 18.1.1.4.2 Strategic choices 282 18.1.1.4.3 Weaknesses and competitive threats 282 18.1.2 F. HOFFMANN-LA ROCHE LTD 283 18.1.2.1 Business overview 283 18.1.2.2 Products offered 284 18.1.2.3 Recent developments 286 18.1.2.3.1 Product launches & approvals 286 18.1.2.4 MnM view 286 18.1.2.4.1 Key strengths 286 18.1.2.4.2 Strategic choices 286 18.1.2.4.3 Weaknesses and competitive threats 287 18.1.3 BECTON, DICKINSON AND COMPANY (BD) 288 18.1.3.1 Business overview 288 18.1.3.2 Products offered 289 18.1.3.3 MnM view 291 18.1.3.3.1 Key strengths 291 18.1.3.3.2 Strategic choices 291 18.1.3.3.3 Weaknesses and competitive threats 291 18.1.4 ABBOTT 292 18.1.4.1 Business overview 292 18.1.4.2 Products offered 293 18.1.4.3 MnM view 294 18.1.4.3.1 Key strengths 294 18.1.4.3.2 Strategic choices 294 18.1.4.3.3 Weaknesses & competitive threats 294 18.1.5 THERMO FISHER SCIENTIFIC INC. 295 18.1.5.1 Business overview 295 18.1.5.2 Products offered 296 18.1.5.3 Recent developments 298 18.1.5.3.1 Expansions 298 18.1.5.4 MnM view 298 18.1.5.4.1 Key strengths 298 18.1.5.4.2 Strategic choices 298 18.1.5.4.3 Weaknesses and competitive threats 298 18.1.6 SIEMENS HEALTHINEERS AG 299 18.1.6.1 Business overview 299 18.1.6.2 Products offered 300 18.1.6.3 Recent developments 302 18.1.6.3.1 Deals 302 18.1.6.3.2 Expansions 302 18.1.7 BIOMÉRIEUX 303 18.1.7.1 Business overview 303 18.1.7.2 Products offered 305 18.1.8 SYSMEX CORPORATION 306 18.1.8.1 Business overview 306 18.1.8.2 Products offered 307 18.1.8.3 Recent developments 308 18.1.8.3.1 Deals 308 18.1.9 BIO-RAD LABORATORIES 309 18.1.9.1 Business overview 309 18.1.9.2 Products offered 310 18.1.10 QIAGEN 312 18.1.10.1 Business overview 312 18.1.10.2 Products offered 313 18.1.10.3 Recent developments 314 18.1.10.3.1 Product launches and approvals 314 18.1.11 REVVITY 315 18.1.11.1 Business overview 315 18.1.11.2 Products offered 317 18.1.12 DIASORIN S.P.A. 318 18.1.12.1 Business overview 318 18.1.12.2 Products offered 319 18.1.13 HORIBA, LTD. 321 18.1.13.1 Business overview 321 18.1.13.2 Products offered 323 18.2 OTHER PLAYERS 324 18.2.1 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 324 18.2.2 VIRCELL S.L. 325 18.2.3 FUJIREBIO 326 18.2.4 ERBA GROUP 327 18.2.5 GUANGZHOU WONDFO BIOTECH CO., LTD. 328 18.2.6 MESO SCALE DIAGNOSTICS, LLC 329 18.2.7 RANDOX LABORATORIES LTD. 330 18.2.8 AMPRION DIAGNOSTICS 331 18.2.9 ATILA BIOSYSTEMS 332 18.2.10 QUANTERIX 333 18.2.11 ALAMAR BIOSCIENCES 334 18.2.12 GENEPROOF 335 19 RESEARCH METHODOLOGY 336 19.1 RESEARCH DATA 336 19.1.1 SECONDARY DATA 337 19.1.1.1 List of secondary sources 337 19.1.1.2 Key data from secondary sources 338 19.1.2 PRIMARY DATA 338 19.1.2.1 List of primary sources 339 19.1.2.2 Key data from primary sources 339 19.1.2.3 Key industry insights 340 19.1.2.4 Breakdown of primary interviews 341 19.2 MARKET SIZE ESTIMATION 341 19.2.1 TOTAL MARKET SIZE: BODY FLUID ANALYSIS MARKET 341 19.2.2 BOTTOM-UP APPROACH 341 19.2.2.1 Approach 1: Revenue estimation of key players 342 19.2.2.2 Approach 2: Study of annual reports and investor presentations 342 19.2.2.3 Approach 3: Primary interviews 342 19.2.2.4 Growth forecast 343 19.2.2.5 CAGR projections 343 19.2.3 TOP-DOWN APPROACH 344 19.3 DATA TRIANGULATION 345 19.4 RESEARCH ASSUMPTIONS 345 19.4.1 STUDY-RELATED ASSUMPTIONS 345 19.5 STUDY ASSUMPTIONS 346 19.5.1 PARAMETRIC ASSUMPTIONS 346 19.5.2 GROWTH RATE ASSUMPTIONS 347 19.6 RESEARCH LIMITATIONS 347 19.7 RISK ASSESSMENT 347 20 APPENDIX 348 20.1 DISCUSSION GUIDE 348 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 352 20.3 CUSTOMIZATION OPTIONS 354 20.4 RELATED REPORTS 354 20.5 AUTHOR DETAILS 355

TABLE 1 BODY FLUID ANALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 58 TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 59 TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS 61 TABLE 4 NORTH AMERICA: COUNTRY-WISE MACROECONOMIC INDICATORS 61 TABLE 5 EUROPE: MACROECONOMIC INDICATORS 61 TABLE 6 ASIA PACIFIC: MACROECONOMIC INDICATORS 61 TABLE 7 LATIN AMERICA: MACROECONOMIC INDICATORS 62 TABLE 8 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 62 TABLE 9 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 67 TABLE 10 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY REGION, 2024–2026 (USD) 67 TABLE 11 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 68 TABLE 12 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 69 TABLE 13 BODY FLUID ANALYSIS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 70 TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 74 TABLE 15 KEY PATENTS IN BODY FLUID ANALYSIS MARKET, 2022–2026 83 TABLE 16 KEY COMPANIES IMPLEMENTING AI IN BODY FLUID ANALYSIS MARKET 87 TABLE 17 CLASSIFICATION OF IVD DEVICES IN EUROPE 89 TABLE 18 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 91 TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 98 TABLE 25 KEY BUYING CRITERIA, BY PRODUCT 98 TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES 99 TABLE 27 BODY FLUID ANALYSIS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 101 TABLE 28 BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 105 TABLE 29 CONSUMABLES OFFERED BY KEY PLAYERS 106 TABLE 30 BODY FLUID ANALYSIS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 107 TABLE 31 NORTH AMERICA: BODY FLUID ANALYSIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 107 TABLE 32 EUROPE: BODY FLUID ANALYSIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 108 TABLE 33 ASIA PACIFIC: BODY FLUID ANALYSIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 108 TABLE 34 TESTING INSTRUMENTS OFFERED BY KEY PLAYERS 109 TABLE 35 BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 110 TABLE 36 NORTH AMERICA: BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110 TABLE 37 EUROPE: BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111 TABLE 38 ASIA PACIFIC: BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111 TABLE 39 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 113 TABLE 40 MICROSCOPIC EXAMINATION-BASED TESTS AND DEVICES OFFERED BY KEY PLAYERS 114 TABLE 41 BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 42 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 43 EUROPE: BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 44 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 45 CLINICAL CHEMISTRY TECHNOLOGY-BASED TESTS AND DEVICES OFFERED BY KEY PLAYERS 117 TABLE 46 BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 47 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 48 EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 49 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 50 BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 51 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 52 EUROPE: BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 53 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 54 IMMUNOASSAY PRODUCTS OFFERED BY KEY PLAYERS 123 TABLE 55 BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 56 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 57 EUROPE: BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 58 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 59 PCR-BASED TESTS AND DEVICES OFFERED BY KEY PLAYERS 126 TABLE 60 BODY FLUID ANALYSIS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 61 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 62 EUROPE: BODY FLUID ANALYSIS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 63 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 64 BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 65 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 66 EUROPE: BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 67 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 68 BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 132 TABLE 69 BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 70 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 71 EUROPE: BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 72 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 73 DIAGNOSTIC PRODUCTS OFFERED BY KEY PLAYERS 135 TABLE 74 BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 75 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 76 EUROPE: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 77 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 78 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 140 TABLE 79 BODY FLUID ANALYSIS MARKET FOR CSF, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 80 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CSF, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 81 EUROPE: BODY FLUID ANALYSIS MARKET FOR CSF, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 82 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CSF, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 83 BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 84 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 85 EUROPE: BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 86 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 87 BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 88 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 89 EUROPE: BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 90 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 91 BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 92 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 93 EUROPE: BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 94 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 95 BODY FLUID ANALYSIS MARKET FOR SEMEN, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 96 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR SEMEN, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 97 EUROPE: BODY FLUID ANALYSIS MARKET FOR SEMEN, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 98 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR SEMEN, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 99 BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 100 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 101 EUROPE: BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 102 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 103 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (IN THOUSANDS) 156 TABLE 104 BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 158 TABLE 105 BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 159 TABLE 106 BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 107 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 108 EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 109 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 110 INFECTIOUS DISEASE PRODUCTS OFFERED BY KEY PLAYERS 162 TABLE 111 BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 162 TABLE 112 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 113 EUROPE: BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 114 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 115 TUBERCULOSIS TESTING PRODUCTS OFFERED BY KEY PLAYERS 165 TABLE 116 BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2024–2031 (USD MILLION) 165 TABLE 117 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 118 EUROPE: BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 119 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 120 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS 2040 167 TABLE 121 BODY FLUID ANALYSIS MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION) 168 TABLE 122 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 123 EUROPE: BODY FLUID ANALYSIS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 124 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 125 BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES, BY REGION, 2024–2031 (USD MILLION) 170 TABLE 126 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 127 EUROPE: BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 128 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 129 BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 130 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 131 EUROPE: BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 132 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 133 BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY REGION, 2024–2031 (USD MILLION) 175 TABLE 134 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 135 EUROPE: BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 136 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 137 BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 179 TABLE 138 BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 180 TABLE 139 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 140 EUROPE: BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 141 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 142 BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 183 TABLE 143 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 144 EUROPE: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 145 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 146 BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 185 TABLE 147 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 148 EUROPE: BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 149 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 150 BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 188 TABLE 151 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 152 EUROPE: BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 153 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 154 BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 190 TABLE 155 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 156 EUROPE: BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 157 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 158 BODY FLUID ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION) 194 TABLE 159 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 160 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 197 TABLE 161 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 197 TABLE 162 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 163 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 198 TABLE 164 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 198 TABLE 165 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 166 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 199 TABLE 167 US: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 200 TABLE 168 US: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 201 TABLE 169 US: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 170 US: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 202 TABLE 171 US: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 202 TABLE 172 US: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 173 US: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 203 TABLE 174 CANADA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 204 TABLE 175 CANADA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 205 TABLE 176 CANADA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 177 CANADA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 206 TABLE 178 CANADA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 206 TABLE 179 CANADA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 180 CANADA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 207 TABLE 181 EUROPE: BODY FLUID ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 182 EUROPE: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 209 TABLE 183 EUROPE: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 209 TABLE 184 EUROPE: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 185 EUROPE: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 210 TABLE 186 EUROPE: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 210 TABLE 187 EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 188 EUROPE: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 211 TABLE 189 GERMANY: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 212 TABLE 190 GERMANY: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 213 TABLE 191 GERMANY: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 192 GERMANY: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 214 TABLE 193 GERMANY: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 214 TABLE 194 GERMANY: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 195 GERMANY: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 215 TABLE 196 UK: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 217 TABLE 197 UK: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 217 TABLE 198 UK: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 199 UK: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 218 TABLE 200 UK: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218 TABLE 201 UK: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 202 UK: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 219 TABLE 203 FRANCE: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 220 TABLE 204 FRANCE: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 220 TABLE 205 FRANCE: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 206 FRANCE: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 221 TABLE 207 FRANCE: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 221 TABLE 208 FRANCE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 209 FRANCE: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 222 TABLE 210 ITALY: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 223 TABLE 211 ITALY: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 224 TABLE 212 ITALY: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 213 ITALY: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 225 TABLE 214 ITALY: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 225 TABLE 215 ITALY: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 216 ITALY: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 226 TABLE 217 SPAIN: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 227 TABLE 218 SPAIN: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 227 TABLE 219 SPAIN: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 220 SPAIN: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 228 TABLE 221 SPAIN: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 228 TABLE 222 SPAIN: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 223 SPAIN: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 229 TABLE 224 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 230 TABLE 225 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 230 TABLE 226 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 227 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 231 TABLE 228 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 231 TABLE 229 REST OF EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 230 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 232 TABLE 231 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 232 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 235 TABLE 233 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 235 TABLE 234 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 235 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 236 TABLE 236 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 236 TABLE 237 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 238 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 237 TABLE 239 CHINA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 238 TABLE 240 CHINA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 238 TABLE 241 CHINA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 242 CHINA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 239 TABLE 243 CHINA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 239 TABLE 244 CHINA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 245 CHINA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 240 TABLE 246 JAPAN: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 241 TABLE 247 JAPAN: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 241 TABLE 248 JAPAN: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 249 JAPAN: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 242 TABLE 250 JAPAN: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 242 TABLE 251 JAPAN: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 252 JAPAN: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 243 TABLE 253 INDIA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 244 TABLE 254 INDIA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 245 TABLE 255 INDIA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 256 INDIA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 246 TABLE 257 INDIA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246 TABLE 258 INDIA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 259 INDIA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 247 TABLE 260 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 248 TABLE 261 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 249 TABLE 262 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 263 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 250 TABLE 264 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 250 TABLE 265 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 266 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 251 TABLE 267 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 253 TABLE 268 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 253 TABLE 269 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 270 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 254 TABLE 271 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 254 TABLE 272 LATIN AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 273 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 255 TABLE 274 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 256 TABLE 275 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 257 TABLE 276 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 277 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 258 TABLE 278 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 258 TABLE 279 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 280 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 281 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN BODY FLUID ANALYSIS MARKET, JANUARY 2023-JUNE 2026 260 TABLE 282 BODY FLUID ANALYSIS MARKET: DEGREE OF COMPETITION 263 TABLE 283 BODY FLUID ANALYSIS MARKET: REGION FOOTPRINT 267 TABLE 284 BODY FLUID ANALYSIS MARKET: PRODUCT FOOTPRINT 268 TABLE 285 BODY FLUID ANALYSIS MARKET: TYPE FOOTPRINT 269 TABLE 286 BODY FLUID ANALYSIS MARKET: APPLICATION FOOTPRINT 269 TABLE 287 BODY FLUID ANALYSIS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 272 TABLE 288 BODY FLUID ANALYSIS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 272 TABLE 289 BODY FLUID ANALYSIS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 273 TABLE 290 BODY FLUID ANALYSIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 275 TABLE 291 BODY FLUID ANALYSIS MARKET: DEALS, JANUARY 2023–JUNE 2026 276 TABLE 292 BODY FLUID ANALYSIS: EXPANSIONS, JANUARY 2023–JUNE 2026 277 TABLE 293 DANAHER: COMPANY OVERVIEW 278 TABLE 294 DANAHER: PRODUCTS OFFERED 279 TABLE 295 DANAHER: DEALS, JANUARY 2023–JUNE 2026 281 TABLE 296 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 283 TABLE 297 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 284 TABLE 298 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 286 TABLE 299 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 288 TABLE 300 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 289 TABLE 301 ABBOTT: COMPANY OVERVIEW 292 TABLE 302 ABBOTT: PRODUCTS OFFERED 293 TABLE 303 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 295 TABLE 304 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 296 TABLE 305 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–APRIL 2026 298 TABLE 306 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 299 TABLE 307 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 300 TABLE 308 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023–APRIL 2026 302 TABLE 309 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023–APRIL 2026 302 TABLE 310 BIOMÉRIEUX: COMPANY OVERVIEW 303 TABLE 311 BIOMÉRIEUX: PRODUCTS OFFERED 305 TABLE 312 SYSMEX: COMPANY OVERVIEW 306 TABLE 313 SYSMEX CORPORATION: PRODUCTS OFFERED 307 TABLE 314 SYSMEX CORPORATION: DEALS, JANUARY 2023–APRIL 2026 308 TABLE 315 BIO-RAD LABORATORIES: COMPANY OVERVIEW 309 TABLE 316 BIO-RAD LABORATORIES: PRODUCTS OFFERED 310 TABLE 317 QIAGEN: COMPANY OVERVIEW 312 TABLE 318 QIAGEN: PRODUCTS OFFERED 313 TABLE 319 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024 314 TABLE 320 REVVITY: COMPANY OVERVIEW 315 TABLE 321 REVVITY: PRODUCTS OFFERED 317 TABLE 322 DIASORIN S.P.A.: COMPANY OVERVIEW 318 TABLE 323 DIASORIN S.P.A.: PRODUCTS OFFERED 319 TABLE 324 HORIBA, LTD.: COMPANY OVERVIEW 321 TABLE 325 HORIBA LTD.: PRODUCTS OFFERED 323 TABLE 326 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 324 TABLE 327 VIRCELL S.L.: COMPANY OVERVIEW 325 TABLE 328 FUJIREBIO: COMPANY OVERVIEW 326 TABLE 329 ERBA GROUP: COMPANY OVERVIEW 327 TABLE 330 GUANGZHOU WONDFO BIOTECH CO., LTD.: COMPANY OVERVIEW 328 TABLE 331 MESO SCALE DIAGNOSTICS LLC: COMPANY OVERVIEW 329 TABLE 332 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 330 TABLE 333 AMPRION DIAGNOSTICS: COMPANY OVERVIEW 331 TABLE 334 ATILA BIOSYSTEMS: COMPANY OVERVIEW 332 TABLE 335 QUANTERIX: COMPANY OVERVIEW 333 TABLE 336 ALAMAR BIOSCIENCES: COMPANY OVERVIEW 334 TABLE 337 GENEPROOF: COMPANY OVERVIEW 335 TABLE 338 BODY FLUID ANALYSIS MARKET: RISK ASSESSMENT 347 FIGURE 1 BODY FLUID ANALYSIS MARKET SEGMENTATION 31 FIGURE 2 KEY INSIGHTS AND MARKET HIGHLIGHTS 35 FIGURE 3 GLOBAL BODY FLUID ANALYSIS MARKET, 2024–2031 35 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BODY FLUID ANALYSIS MARKET, 2023–2025 36 FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF BODY FLUID ANALYSIS 37 FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN BODY FLUID ANALYSIS MARKET, 2025 38 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 39 FIGURE 8 RISING CASES OF CHRONIC DISEASES TO DRIVE MARKET 40 FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 40 FIGURE 10 CLINICAL CHEMISTRY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 41 FIGURE 11 DIAGNOSTIC PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 41 FIGURE 12 CEREBROSPINAL FLUID TO LEAD MARKET DURING FORECAST PERIOD 42 FIGURE 13 CLINICAL DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 42 FIGURE 14 HOSPITAL LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 43 FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 43 FIGURE 16 BODY FLUID ANALYSIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 44 FIGURE 17 BODY FLUID ANALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 57 FIGURE 18 BODY FLUID ANALYSIS MARKET: SUPPLY CHAIN ANALYSIS 63 FIGURE 19 BODY FLUID ANALYSIS MARKET: VALUE CHAIN ANALYSIS 64 FIGURE 20 BODY FLUID ANALYSIS MARKET: ECOSYSTEM ANALYSIS 65 FIGURE 21 BODY FLUID ANALYSIS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71 FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN BODY FLUID ANALYSIS MARKET 72 FIGURE 23 PATENT ANALYSIS FOR BODY FLUID ANALYSIS, JANUARY 2016–DECEMBER 2025 82 FIGURE 24 MARKET POTENTIAL OF AI IN BODY FLUID ANALYSIS MARKET 86 FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 97 FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT 98 FIGURE 27 NORTH AMERICA: BODY FLUID ANALYSIS MARKET SNAPSHOT 196 FIGURE 28 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET SNAPSHOT 234 FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN BODY FLUID ANALYSIS MARKET, 2023–2025 (USD MILLION) 262 FIGURE 30 BODY FLUID ANALYSIS MARKET SHARE ANALYSIS, 2025 (GLOBAL) 263 FIGURE 31 US BODY FLUID ANALYSIS MARKET SHARE ANALYSIS, 2025 (US) 265 FIGURE 32 BODY FLUID ANALYSIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 266 FIGURE 33 BODY FLUID ANALYSIS MARKET: COMPANY FOOTPRINT 267 FIGURE 34 BODY FLUID ANALYSIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 271 FIGURE 35 EV/EBITDA OF KEY VENDORS 273 FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 274 FIGURE 37 BODY FLUID ANALYSIS MARKET: PRODUCT COMPARISON FOR BODY FLUID ANALYSIS 274 FIGURE 38 DANAHER: COMPANY SNAPSHOT (2025) 279 FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 284 FIGURE 40 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025) 289 FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2025) 293 FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 296 FIGURE 43 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 300 FIGURE 44 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 304 FIGURE 45 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025) 307 FIGURE 46 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2025) 310 FIGURE 47 QIAGEN: COMPANY SNAPSHOT (2025) 313 FIGURE 48 REVVITY: COMPANY SNAPSHOT (2025) 316 FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 319 FIGURE 50 HORIBA, LTD.: COMPANY SNAPSHOT (2025) 322 FIGURE 51 RESEARCH DESIGN 336 FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 341 FIGURE 53 TOP-DOWN APPROACH 344 FIGURE 54 DATA TRIANGULATION 345